Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway
文献类型：期刊论文
| 作者 | Li, Ming3; Shan, Wulin3; Hua, Yan3; Chao, Fengmei3; Cui, Yayun3; Lv, Lei3; Dou, Xiaoyan3; Bian, Xing1,2,3; Zou, Jinglu1,2; Li, Hong1,2
|
| 刊名 | FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
 |
| 出版日期 | 2021-05-31 |
| 卷号 | 9 |
| ISSN号 | 2296-634X |
| 关键词 | exosome miR-92b-3p small cell lung cancer chemoresistance migration |
| DOI | 10.3389/fcell.2021.661602 |
| 通讯作者 | Li, Ming(liming19831002@163.com) ; Lin, Wenchu(wenchu@hmfl.ac.cn) |
| 英文摘要 | Resistance to first-line chemotherapy drugs has become an obstacle to improving the clinical prognosis of patients with small cell lung cancer (SCLC). Exosomal microRNAs have been shown to play pro- and anti-chemoresistant roles in various cancers, but their role in SCLC chemoresistance has never been explored. In this study, we observed that the expression of exosomal miR-92b-3p was significantly increased in patients who developed chemoresistance. Luciferase reporter analysis confirmed that PTEN was a target gene of miR-92b-3p. The PTEN/AKT regulatory network was related to miR-92b-3p-mediated cell migration and chemoresistance in vitro and in vivo in SCLC. Importantly, exosomes isolated from the conditioned medium of SBC-3 cells overexpressing miR-92b-3p could promote SCLC chemoresistance and cell migration. Furthermore, we found that plasma miR-92b-3p levels were significantly higher in patients with chemoresistant SCLC than in those with chemosensitive SCLC, but the levels were down-regulated in patients who achieved remission. Kaplan-Meier analysis showed that SCLC patients with high miR-92b-3p expression were associated with shorter progression-free survival. Overall, our results suggested that exosomal miR-92b-3p is a potential dynamic biomarker to monitor chemoresistance in SCLC and represents a promising therapeutic target for chemoresistant SCLC. |
| WOS关键词 | CISPLATIN RESISTANCE ; MULTIDRUG-RESISTANCE ; PROLIFERATION ; MICRORNAS ; TUMORS |
| 资助项目 | Natural Science Foundation of Anhui Province[2008085MH288] ; National Natural Science Foundation of China[81972191] ; Science and Technology Major Project of Anhui Province[18030801140] ; Fundamental Research Funds for Central University[WK9110000025] ; Fundamental Research Funds for Central University[WK9110000072] ; Fundamental Research Funds for Central University[WK9110000071] ; National Cancer Center Climbing Funds[NCC201812B036] ; High Magnetic Field Laboratory of Anhui Province |
| WOS研究方向 | Cell Biology ; Developmental Biology |
| 语种 | 英语 |
| 出版者 | FRONTIERS MEDIA SA |
| WOS记录号 | WOS:000661168100001 |
| 资助机构 | Natural Science Foundation of Anhui Province ; National Natural Science Foundation of China ; Science and Technology Major Project of Anhui Province ; Fundamental Research Funds for Central University ; National Cancer Center Climbing Funds ; High Magnetic Field Laboratory of Anhui Province |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/123914]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Li, Ming; Lin, Wenchu |
| 作者单位 | 1.Chinese Acad Sci, Hefei Inst Phys Sci, High Field Magnet Lab, Hefei, Peoples R China 2.Chinese Acad Sci, Hefei Inst Phys Sci, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei, Peoples R China 3.Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Dept Lab Diagnost,USTC, Hefei, Peoples R China |
| 推荐引用方式 GB/T 7714 | Li, Ming,Shan, Wulin,Hua, Yan,et al. Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway[J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY,2021,9. |
| APA | Li, Ming.,Shan, Wulin.,Hua, Yan.,Chao, Fengmei.,Cui, Yayun.,...&Lin, Wenchu.(2021).Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway.FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY,9. |
| MLA | Li, Ming,et al."Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway".FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY 9(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。